Bavarian Nordic A/S
Research Bavarian Nordic A/S (BV3A) on Bullrun: market cap EUR 2.09B, P/E 10.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBV3A
- ExchangeF
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.09B
- P/E10.7
- Financial periodQ1 2026
- RevenueDKK 1.06B
- Net incomeDKK 16.95M
- Free cash flow-DKK 810.26M
- Gross margin44.8%
Valuation Snapshot
latest market cap is EUR 2.09B; P/E is 10.7.
Peer valuation comparison
Latest P/E is 10.7x versus a Healthcare sector median of 24.46x (56.3% below).
Latest P/E is 10.7x versus a Denmark median of 19.06x (43.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 6.24B | DKK 1.38B | DKK 1.36B | 48.8% | n/a | DKK 1.71B | DKK 130.87M | DKK 12.87B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 2.09B | 10.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bavarian Nordic A/S's market cap?
Bavarian Nordic A/S's market capitalization is EUR 2.09B.
What is Bavarian Nordic A/S's P/E ratio?
Bavarian Nordic A/S's price-to-earnings (P/E) ratio is 10.7.
What does Bavarian Nordic A/S do?
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.